H35.143
Retinopathy of prematurity, stage 3, bilateral
Clinical Classification Guidelines
Medical Intelligence & Overview
Retinopathy of Prematurity (ROP) is a condition that affects the developing blood vessels in the eyes of premature infants. When these blood vessels grow abnormally, they can potentially lead to vision problems or blindness. ICD-10 code H35.143 specifically describes stage 3 ROP affecting both eyes. Recognizing the severity and progression of this stage is essential for appropriate management and intervention. This guide provides an overview suited for patients and caregivers seeking a better understanding of this condition.
Causes & Symptoms
Clinical Causes: Premature birth: infants born before 31 weeks of gestation or with very low birth weights are at higher risk. High levels of oxygen therapy: excessive oxygen administration during neonatal care can disrupt normal retinal blood vessel development. Genetic predispositions: certain genetic factors may influence susceptibility to abnormal blood vessel growth. Birth complications: conditions such as respiratory distress or patent ductus arteriosus (PDA) can contribute to the development of ROP.
Key Symptoms: No immediate symptoms in early stages; typically detected during screening examinations. If advanced, signs may include abnormal eye movements or crossed eyes. In severe cases, infants may develop cloudiness in the eye or have signs of visual impairment.
Diagnostic & Treatment
Diagnosis Path: Diagnosis is primarily performed through screening eye examinations by ophthalmologists trained in neonatal care. During these exams, doctors inspect the retina using specialized magnifying lenses and ophthalmoscopes. The staging of ROP, including stage 3, is determined based on the extent and severity of abnormal blood vessel growth and scarring visible in these exams. Regular screening is crucial for infants at risk to identify progression and determine timely intervention.
Treatment Protocols: The management of stage 3 ROP involves various approaches aimed at halting abnormal blood vessel growth and preventing progression to more severe stages. Treatment options often include: - Laser therapy: Using laser beams to shrink abnormal blood vessels and reduce the risk of retinal detachment. - Cryotherapy: Applying extreme cold to ablate avascular retina regions, less common today but still used in certain cases. - Intravitreal injections: Medications such as anti-VEGF agents may be administered to inhibit abnormal vessel growth. In some cases, close monitoring is adopted if the disease does not progress, while prompt intervention is necessary if the condition worsens. Follow-up examinations are essential to assess treatment efficacy and retinal health.
Clinical Advice & FAQs
Billing Guidance
Is H35.143 a billable ICD-10 code?
Yes, H35.143 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report H35.143?
Clinical documentation must specify the nature of Retinopathy of prematurity, stage 3, bilateral and any associated comorbidities for accurate reporting.
Cite this Clinical Reference